Robotic assisted cytoreductive surgery, removal of a recurrent disease in the right pericaval lymph node in a patient with ovarian cancer with the robotic Xi platform
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
ObjectiveThe standard approach for recurrent ovarian cancer is laparotomy. In this video, we present a cytoreductive surgeryusing the robotic Xi platform to remove a 2.7 cm pericaval tumor. MethodsA narrative video demonstration of robotic-assisted surgery to remove recurrent ovarian cancer in a pericaval lymphnode. A 62-year-old female presented with recurrent carcinoma of the pericaval lymph node. After 40 months ofsurveillance, the patient was asymptomatic, but a computed tomography (CT) scan showed an isolated mass (2.7×2.3 cm)in the right pericaval lymph node. Her cancer antigen (CA)-125 level increased from 26 to 46 U/mL. The robotic Xiplatform was used to remove the metastatic lymph nodes. The first step was diagnostic laparoscopy. The second stepwas robotic port placement below the umbilicus. The third step was dissection and identification of landmarks, andthe last step was removal of the tumor and closure. ResultsThe metastatic lymph nodes were removed. The patient was discharged on postoperative day 1 and had nopostoperative complications. Her CA-125 level dropped to 17 U/mL two weeks after surgery. Pathology showedmetastatic high-grade serous carcinoma in one lymph node, consistent with the patient’s known primary. Twoadditional lymph nodes were removed and negative for carcinoma. Pelvic washings were negative for malignancy. ConclusionRobotic-assisted surgery is safe and feasible in selected patients with isolated recurrent disease.
Abstract
ObjectiveThe standard approach for recurrent ovarian cancer is laparotomy. In this video, we present a cytoreductive surgeryusing the robotic Xi platform to remove a 2.7 cm pericaval tumor. MethodsA narrative video demonstration of robotic-assisted surgery to remove recurrent ovarian cancer in a pericaval lymphnode. A 62-year-old female presented with recurrent carcinoma of the pericaval lymph node. After 40 months ofsurveillance, the patient was asymptomatic, but a computed tomography (CT) scan showed an isolated mass (2.7×2.3 cm)in the right pericaval lymph node. Her cancer antigen (CA)-125 level increased from 26 to 46 U/mL. The robotic Xiplatform was used to remove the metastatic lymph nodes. The first step was diagnostic laparoscopy. The second stepwas robotic port placement below the umbilicus. The third step was dissection and identification of landmarks, andthe last step was removal of the tumor and closure. ResultsThe metastatic lymph nodes were removed. The patient was discharged on postoperative day 1 and had nopostoperative complications. Her CA-125 level dropped to 17 U/mL two weeks after surgery. Pathology showedmetastatic high-grade serous carcinoma in one lymph node, consistent with the patient’s known primary. Twoadditional lymph nodes were removed and negative for carcinoma. Pelvic washings were negative for malignancy. ConclusionRobotic-assisted surgery is safe and feasible in selected patients with isolated recurrent disease.
참고문헌 (9)
- AGO Studiengruppe Harter P, "Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer-final analysis of AGO DESKTOP III", ENGOT- ov20, 2020, pp.80, e79~
- Rongyu Zang, "A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1", SGOG-OV2., 2020, pp.38(15_suppl), 6001~6001[DOI]
- Coleman RL, "Secondary surgical cytoreduction for recurrent ovarian cancer", N Engl J Med, 381, pp.1929~1939 (2019)
- Feuer GA, "Perioperative and clinical outcomes in the management of epithelial ovarian cancer using a robotic or abdominal approach", Gynecol Oncol, 131, pp.520~524 (2013)
- Holloway RW, "Robotic-assisted resection of liver and diaphragm recurrent ovarian carcinoma : description of technique", Gynecol Oncol, 120, pp.419~422 (2011)
- Escobar PF, "Feasibility and perioperative out comes of robotic-assisted surgery in the management of recurrent ovarian cancer : a multi-institutional study", Gynecol Oncol, 134, pp.253~256 (2014)
- Magrina JF, "Analysis of secondary cytoreduction for recurrent ovarian cancer by robotics, laparoscopy and laparotomy", Gynecol Oncol, 129, pp.336~340 (2013)
- Nezhat FR, "Comparison of perioperative outcomes and complication rates between conventional versus robotic-assisted laparoscopy in the evaluation and management of early, advanced, and recurrent stage ovarian, fallopian tube, and primary peritoneal cancer", Int J Gynecol Cancer, 24, pp.600~607 (2014)
- "NCCN clinical practice guide-lines: ovarian cancer. Version: 1.2021" (2021)[URL]